Mar 15 |
Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58%
|
Jan 22 |
Roche ends AC Immune partnership for Alzheimer’s drugs
|
Jan 22 |
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
|
Jan 18 |
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
|
Jan 8 |
5 Small-Cap Stocks to Play the January Effect
|
Jan 3 |
AC Immune (ACIU) Upgraded to Buy: Here's Why
|
Jan 3 |
AC Immune issues updates on Phase 2 studies, cash runway
|
Jan 3 |
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
|
Dec 18 |
AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts
|
Dec 15 |
AC Immune Alzheimer's drug advanced into Phase 2b testing
|